Meds, Meds and MORE Meds....

[Guest guest]

Therapeutics Daily <news@...> wrote: From: "Therapeutics Daily" <news@...>sophya_lauren@...Date: 11 Feb 2008 08:04:51 -0500Subject: CNS Weekly -AstraZeneca Seeks Summary Judgment Over Seroquel If you are having problems viewing this message, please use this link View All CNS News | Manage Subscriptions | TherapeuticsDaily.com Monday February 11, 2008 sponsored by: AstraZeneca Seeks Summary Judgment Over SeroquelFrom Reuters Health - Feb 08, 2008LONDON (Reuters) - AstraZeneca Plc is trying to head off the threat of generic competition to its blockbuster schizophrenia drug Seroquel by seeking a summary judgment in a U.S. court case, the Anglo-Swedish drugmaker said on Friday. Lawyers for the company this week requested leave to file for a motion for summary judgment in the District Court of New Jersey in a patent dispute with Teva Pharmaceutical Industries Ltd, a spokeswoman said. Read Full Article Article Summary Featured Solutions Provider PharmaLiveSearch.com NOW AVAILABLEPharmaLiveSearch.com is the only pharmaceutical search engine. Scouring 4,000 relevant sources for the information you need, PharmaLiveSearch.com generates more precise results than general search engines, eliminating irrelevant links. What's more, PharmaLiveSearch.com gives you the ability to broaden or narrow your search terms, recommends related search terms, and lists the most popular searches. Use this link to get started with PharmaLiveSearch.com. FDA Panel Backs Long-Acting ZyprexaFrom New York Times - Feb 07, 2008A federal advisory panel has backed Eli Lilly & Company's proposed long-acting form of its schizophrenia drug Zyprexa. Advisers to the FDA said Wednesday that the experimental injectable formulation appeared effective and was acceptably safe for treating stable patients as well as those with acute symptom flare-ups. The vote on the drug's effectiveness was unanimous, and 10 to 0 with one abstention that the risks were acceptable. Read Full Article Article Summary FDA Extends Requip Review PeriodFrom Market Wire - Feb 05, 2008LONDON, UK, 5 February 2008-- SkyePharma PLC has been informed that the FDA has extended the Prescription Drug User Fee Act (PDUFA) action date for GlaxoKline's Requip XL Extended Release tablets. The PDUFA action date is the date by which the FDA is expected to issue a response on a pending new drug application. Following the approvable letter for Requip XL issued in December 2007, GlaxoKline submitted a response to the FDA. Read Full Article Article Summary Sen. Grassley Letter to Pharmaceutical Drug Maker About Notice of Drug Trial FindingsFrom PharmaLive News Archive - Feb 07, 2008WASHINGTON, February 6, 2008 - Sen. Chuck Grassley is asking drug maker

GlaxoKline for documents regarding the antidepressant medication Paxil. Sen. Grassley is making his request based on a review of documents recently made public and reported today in the magazine New Scientist. Read Full Article Article Summary Aurobindo Pharma Gets US Nod for Prozac

GenericFrom Reuters Health - Feb 05, 2008MUMBAI (Reuters) - Drug maker Aurobindo Pharma Ltd has received the FDA approval for its fluoxetine hydrochloride and gabapentin capsules in multiple strength, the regulator's Web site showed on Tuesday. Read Full Article Article Summary Wockhardt Gets U.S. Nod for Phenytoin Sodium Capsule From Reuters Health - Feb 01, 2008MUMBAI (Reuters) - The U.S. Food and Drug Administration has approved the sale of Wockhardt Ltd's extended phenytoin sodium capsule in that country, the agency's website showed on Friday. The drug is prescribed for epileptic seizures. Read Full Article Article Summary Neurogen Announces R & D UpdateFrom Business Wire NewsExpress - Feb 08, 2008BRANFORD, Conn.--(BUSINESS WIRE)--Feb 8, 2008 - Neurogen Corporation today updated the status of its later stage clinical portfolio and announced the future focus of its research efforts. Neurogen intends to pursue five unpartnered clinical programs in 2008 to address anxiety, insomnia, Restless Legs Syndrome (RLS), Parkinson's disease and schizophrenia. Read Full Article Article Summary EpiCept Announces Encouraging Results of Phase II Trial for NP-1 Cream in Diabetic Peripheral Neuropathy From PharmaLive News Archive - Feb 07, 2008TARRYTOWN, N.Y.--Feb. 7, 2008--EpiCept Corporation today announced preliminary results from its Phase II "Neuracept" trial for EpiCept NP-1 Cream in patients

suffering from diabetic peripheral neuropathy (DPN). All pain scores measured trended in favor of the NP-1 treated patients over the placebo group, indicative of an analgesic effect in this type of peripheral neuropathic pain. EpiCept has concluded that preliminary data derived from the trial support the continued study of NP-1 in a late-stage pivotal clinical trial. Read Full Article Article Summary Forest Announces Positive Results of Memantine Study of Once-Daily FormulationFrom PR Newswire - Feb 05, 2008NEW YORK, February 05, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. today announced preliminary results of a Phase III study of memantine HCl (currently marketed as Namenda, a twice-daily immediate- release formulation) in a novel once-daily formulation. The study evaluated the efficacy, safety, and tolerability of an innovative, proprietary, 28 mg memantine extended-release, once-daily formulation compared to placebo in outpatients with moderate to severe Alzheimer's disease currently treated with a cholinesterase inhibitor. Read Full Article Article Summary New Schizophrenia Treatment Now Available in Canada From PharmaLive News Archive - Feb 06, 2008MONTREAL, Feb. 6 /CNW/ - Canadians with schizophrenia now have a new treatment option to manage their disease. Health Canada has approved Zeldox (ziprasidone hydrochloride) for the treatment of

schizophrenia and related psychotic disorders, bringing an important additional option to manage this chronic complex mental illness, which is highly stigmatized and misunderstood. Read Full Article Article Summary paid advertisement Central Nervous System Weekly is brought to you by PharmaLive.com and is a member of the TherapeuticsDaily.com eNewsletter Series.For information on advertising with TherapeuticsDaily.com, please contact Bob Aberman at bob.aberman@....If your Internet provider filters incoming e-mail, please add 'TherapeuticsDaily.com' to your list of approved senders to make sure you receive the email alerts and newsletters to which you subscribe. This e-mail is a transactional/relationship message. TherapeuticsDaily.com has sent you this e-Newsletter because you signed up to receive it. If you would prefer not to receive this email from Canon Communications Pharmaceutical Media Group or wish to update your subscriptions, please manage your subscriptions here. Your request will be completed within 5 business days. ©2008 Canon Communications Pharmaceutical Media Group, 828A Newtown-Yardley Road, Newtown, PA 18940. Click Here to be removed from this list Sophiahttp://justamom2three.blogspot.com/

Be a better friend, newshound, and know-it-all with Mobile. Try it now.